查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493378

美國肝癌診斷市場規模、佔有率和趨勢分析報告：按測試類型、最終用途、地區和細分市場預測，2024-2030 年

U.S. Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國肝癌診斷市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，美國肝癌診斷市場預計到2030年將達到43.7億美元，2024年至2030年複合年成長率為4.4%。

這種成長歸因於肝癌盛行率的增加、肝癌危險因子盛行率的增加以及技術的進步。該國肝癌的高盛行率凸顯了對其預防、檢測和治療的需求。例如，2022年肝癌和肝內膽管癌佔所有新發癌症病例的2.2%。

此外，越來越多的政府計劃和合作努力透過大量投資、資料主導的方法和國家合作來改變該國的癌症預防、檢測、治療和研究，預計將進一步推動市場成長。例如，由美國癌症研究所 (NCI) 癌症預防部門建立的轉化型肝癌 (TLC)聯盟專門致力於改善肝癌的監測、早期檢測和風險分層，其目的是促進轉化型肝癌。

2022 年 2 月啟動的癌症登月舉措強調了合作努力在推進癌症研究、治療和患者照護方面的重要性。 Cancer Moonshot 是一項 2.4 億美元的投資，旨在支持預防、檢測、治療和生存癌症的新方法。這筆資金將透過衛生高級研究計劃局 (ARPA-H) 向從事癌症相關計劃的研究人員和創新者提供。這項投資包括開發早期癌症檢測工具、在手術過程中可視化癌細胞的創新方法、利用細菌靶向癌細胞等新治療方法，以及設計治療設備等更有效的腫瘤檢測舉措。

美國肝癌診斷市場報告亮點

  • 從最終用途來看，醫院和診斷實驗室領域以約 50% 的高佔有率佔據市場主導地位。如此高的比例是由於美國各地醫院數量眾多。
  • 按測試類型分類，在用於癌症研究和診斷的新型生物標記發現的最新趨勢的推動下，分子標記領域預計在預測期內以 9.9% 的最快複合年成長率成長。
  • 臨床檢測產業由於能夠檢測生物標記、促進早期檢測並提供癌症診斷的預後訊息，因此在 2023 年將佔據最大的收入佔有率，約為 40%。
  • 2023 年 1 月，艾米金 (Amy Kim) 和她在約翰霍普金斯大學醫學院的研究團隊開發了一種新的肝癌篩檢測試，利用尿液分離互補的腫瘤DNA，用於癌症檢測。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國肝癌診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國肝癌診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國肝癌診斷市場：檢測類型的估計與趨勢分析

  • 2023 年和 2030 年測試類型市場佔有率
  • 細分儀表板
  • 按測試類型分類的美國肝癌診斷市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 試驗
  • 影像
  • 內視鏡檢查
  • 活體組織切片

第5章美國肝癌診斷市場：最終用途估計與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 按最終用途分類的美國肝癌診斷市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院/診斷實驗室
  • 學術/研究機構
  • 製藥/CRO實驗室

第6章美國肝癌診斷市場：區域估算及趨勢分析

  • 2023 年和 2030 年按地區分類的市場佔有率佔有率
  • 美國肝癌診斷市場區域展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 西
  • 中西部
  • 東北
  • 西南
  • 東南

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • Abbott Laboratories
    • Guardant Health
    • Thermo Fisher Scientific, Inc.
    • Illumina, Inc.
    • F.Hoffmann-La Roche Ltd.
    • Qiagen NV
    • Siemens Healthineers
    • Becton, Dickinson &Company
    • Epigenomics AG
    • Koninklijke Philips NV
    • FUJIFILM Healthcare Americas Corporation
Product Code: GVR-4-68040-290-2

U.S. Liver Cancer Diagnostics Market Growth & Trends:

The U.S. liver cancer diagnostics market is anticipated to reach USD 4.37 billion by 2030, exhibiting a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is attributable to the increasing prevalence of liver cancer, rising prevalence of risk factors for liver cancer, and technological advancements. The significant prevalence of liver cancer in the country highlights the need for its prevention, detection, and treatment. For instance, liver and intrahepatic bile duct cancer accounted for 2.2% of all new cancer cases in 2022.

Moreover, the growing number of government programs and collaborative efforts to transform cancer prevention, detection, treatment, and research in the country through substantial investments, data-driven approaches, and nationwide collaborations are further expected to propel market growth. For instance, the Translational Liver Cancer (TLC) Consortium, established by the National Cancer Institute's (NCI) Division of Cancer Prevention, aims to advance translational research specifically focused on improving surveillance, early detection, and risk stratification of liver cancer.

The Cancer Moonshot initiative initiated in February 2022 highlights the importance of collaborative efforts in advancing cancer research, treatment, and patient care. A significant investment of USD 240 million in the Cancer Moonshot supports new ways to prevent, detect, treat, and survive cancer. This funding is likely channeled through the Advanced Research Projects Agency for Health (ARPA-H) to researchers and innovators working on cancer-related projects. The investment includes initiatives such as developing tools for early cancer detection, innovative approaches for visualizing cancer cells during surgery, novel treatment methods like using bacteria to target cancer cells and designing devices for more effective tumor treatment.

U.S. Liver Cancer Diagnostics Market Report Highlights:

  • In terms of end-use, the hospitals and diagnostic laboratories segment dominated the market with the highest share of around 50%. This high share is attributable to the significant presence of hospitals across the country.
  • Based on test type, the molecular markers segment is expected to grow at the fastest CAGR of 9.9% over the forecast period owing to the recent developments in the discovery of novel biomarkers for cancer research and diagnosis.
  • The laboratory tests segment accounted for the largest revenue share of around 40% in 2023 due to their ability to detect biomarkers, facilitate early detection, and provide prognostic information in cancer diagnosis.
  • In Jan 2023, Amy Kim and her team from Johns Hopkins Medicine developed a new screening test for liver cancer, which uses urine to isolate complementary tumor DNA for cancer detection.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. End-use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Liver Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Liver Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Liver Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Liver Cancer Diagnostics Market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Laboratory Tests
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Biomarker Tests
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.2. Oncofetal And Glycoprotein Antigens
      • 4.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.3. Enzymes And Isoenzymes
      • 4.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.4. Growth Factors and Receptors
      • 4.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.5. Molecular Markers
      • 4.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.6. Pathological Biomarkers
      • 4.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Blood Tests
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Imaging
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Endoscopy
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Biopsy
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Liver Cancer Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. End-use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Liver Cancer Diagnostics Market by End-use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals and Diagnostic Laboratories
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Academic and Research Institutes
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Pharmaceutical and CRO Laboratories
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Liver Cancer Diagnostics Market: Region Estimates & Trend Analysis

  • 6.1. Regional Market Share, 2023 & 2030
  • 6.2. U.S. Liver Cancer Diagnostics Market by Region Outlook
  • 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.3.1. West
      • 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Midwest
      • 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Northeast
      • 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Southwest
      • 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.5. Southeast
      • 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Abbott Laboratories
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Guardant Health
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Thermo Fisher Scientific, Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Illumina, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. F.Hoffmann-La Roche Ltd.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Qiagen N.V.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Siemens Healthineers
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Becton, Dickinson & Company
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Epigenomics AG
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Koninklijke Philips N.V.
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. FUJIFILM Healthcare Americas Corporation
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 3 U.S. liver cancer diagnostics, by end-use, 2018 - 2030 (USD Million)
  • Table 4 U.S. liver cancer diagnostics, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. liver cancer diagnostics market: market outlook
  • Fig. 9 U.S. liver cancer diagnostics market competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. liver cancer diagnostics market driver impact
  • Fig. 14 U.S. liver cancer diagnostics market restraint impact
  • Fig. 15 U.S. liver cancer diagnostics: Test type movement analysis
  • Fig. 16 U.S. liver cancer diagnostics: Test type outlook and key takeaways
  • Fig. 17 Laboratory tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Biomarker tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Oncofetal and glycoprotein antigens market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Enzymes and isoenzymes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Growth factors and receptors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Molecular markers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Pathological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Blood tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Endoscopy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. liver cancer diagnostics: End-use movement analysis
  • Fig. 29 U.S. liver cancer diagnostics: End-use outlook and key takeaways
  • Fig. 30 Hospitals and diagnostic laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Academic and research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pharmaceutical and CRO laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. liver cancer diagnostics market: Regional movement analysis
  • Fig. 34 U.S. liver cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 35 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)